Justin Georgekutty1, Amir Kazerouninia2, YunFei Wang3, Peter R. Ermis4, Dhaval R. Parekh4, Wayne J. Franklin4, Wilson W. Lam4
Congenital Heart Disease, Vol.13, No.4, pp. 541-547, 2018, DOI:10.1111/chd.12603
Abstract Objective: Adult Fontan patients are at increased risk for thrombosis and thromboembolic complications leading to increased morbidity and mortality. Most are prescribed antiplatelet or
anticoagulant therapy for thromboprophylaxis; novel oral anticoagulants (NOACs) are uncommonly
used given lack of data on their use in this population and generalized concerns regarding Fontan
patients’ abnormal coagulation. We report the largest single-center experience with the use of
NOACs for treatment and prophylaxis of thrombosis and thromboembolism in adult Fontan
patients.
Results: A retrospective chart review identified 21 patients (11 female, 10 male), median age 33
years (18-50) at first initiation, who were prescribed a… More >
Login
Register
